Stonehouse P. Jon's most recent trade in Biocryst Pharmaceuticals Inc. was a trade of 61,793 Common Stock done at an average price of $7.4 . Disclosure was reported to the exchange on Dec. 19, 2025.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Biocryst Pharma Inc | Jon P. Stonehouse | Director, Chief Executive Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 7.41 per share. | 19 Dec 2025 | 61,793 | 1,323,429 (0%) | 0% | 7.4 | 457,886 | Common Stock |
| Biocryst Pharma Inc | Jon P. Stonehouse | Director, Chief Executive Officer | Gift of securities by or to the insider at price $ 0.00 per share. | 18 Dec 2025 | 20,000 | 1,385,222 (0%) | 0% | 0 | Common Stock | |
| Biocryst Pharma Inc | Jon P. Stonehouse | Director, Chief Executive Officer | Gift of securities by or to the insider at price $ 0.00 per share. | 18 Dec 2025 | 10,000 | 40,000 (0%) | 0% | 0 | Common Stock | |
| Biocryst Pharma Inc | Jon P. Stonehouse | Director, Chief Executive Officer | Gift of securities by or to the insider at price $ 0.00 per share. | 18 Dec 2025 | 10,000 | 40,000 (0%) | 0% | 0 | Common Stock | |
| Biocryst Pharma Inc | Jon P. Stonehouse | Director, Chief Executive Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 7.57 per share. | 12 Dec 2025 | 27,368 | 1,405,222 (0%) | 0% | 7.6 | 207,176 | Common Stock |
| Metsera Inc | Jon P. Stonehouse | Director | Sale or transfer of securities back to the company at price $ 0.00 per share. | 13 Nov 2025 | 47,730 | 0 | - | - | Stock Option (right to buy) | |
| Metsera Inc | Jon P. Stonehouse | Director | Sale or transfer of securities back to the company at price $ 0.00 per share. | 13 Nov 2025 | 2,688 | 0 | - | - | Common Stock | |
| Metsera Inc | Jon P. Stonehouse | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Nov 2025 | 2,688 | 2,688 | - | - | Restricted Stock Unit | |
| Metsera Inc | Jon P. Stonehouse | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 28 Apr 2025 | 47,730 | 47,730 | - | - | Stock Option (Right to Buy) | |
| Biocryst Pharma Inc | P. Stonehouse Jon | Director, President & CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 19 Dec 2024 | 750,250 | 750,250 | - | - | Emp. Stock Option (Right to Buy) | |
| Biocryst Pharma Inc | Stonehouse Jon P. | Director, President & CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 19 Dec 2024 | 362,100 | 1,463,119 (0%) | 0% | 0 | Common Stock | |
| Biocryst Pharma Inc | Jon Stonehouse P. | Director, President & CEO | Gift of securities by or to the insider at price $ 0.00 per share. | 19 Dec 2024 | 20,000 | 1,429,109 (0%) | 0% | 0 | Common Stock | |
| Biocryst Pharma Inc | Jon P. Stonehouse | Director, President & CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 7.39 per share. | 19 Dec 2024 | 14,010 | 1,449,109 (0%) | 0% | 7.4 | 103,534 | Common Stock |
| Biocryst Pharma Inc | Stonehouse Jon P. | Director, President & CEO | Gift of securities by or to the insider at price $ 0.00 per share. | 19 Dec 2024 | 10,000 | 30,000 (0%) | 0% | 0 | Common Stock | |
| Biocryst Pharma Inc | Jon Stonehouse P. | Director, President & CEO | Gift of securities by or to the insider at price $ 0.00 per share. | 19 Dec 2024 | 10,000 | 30,000 (0%) | 0% | 0 | Common Stock | |
| Biocryst Pharma Inc | Jon P. Stonehouse | Director, President & CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 7.53 per share. | 14 Dec 2024 | 27,525 | 1,101,019 (0%) | 0% | 7.5 | 207,263 | Common Stock |
| Biocryst Pharma Inc | Jon P. Stonehouse | Director, President & CEO | Purchase of securities on an exchange or from another person at price $ 5.55 per share. | 13 May 2024 | 30,000 | 1,127,770 (0%) | 0% | 5.6 | 166,500 | Common Stock |
| Biocryst Pharma Inc | Stonehouse P. Jon | Director, President & CEO | Gift of securities by or to the insider at price $ 0.00 per share. | 03 Jan 2024 | 20,000 | 1,094,770 (0%) | 0% | 0 | Common Stock | |
| Biocryst Pharma Inc | P. Jon Stonehouse | Director, President & CEO | Gift of securities by or to the insider at price $ 0.00 per share. | 03 Jan 2024 | 10,000 | 20,000 (0%) | 0% | 0 | Common Stock | |
| Biocryst Pharma Inc | Jon Stonehouse P. | Director, President & CEO | Gift of securities by or to the insider at price $ 0.00 per share. | 03 Jan 2024 | 10,000 | 20,000 (0%) | 0% | 0 | Common Stock | |
| Biocryst Pharma Inc | Stonehouse P. Jon | Director, President & CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 6.05 per share. | 19 Dec 2023 | 14,089 | 1,114,770 (0%) | 0% | 6.0 | 85,238 | Common Stock |
| Biocryst Pharma Inc | Jon P. Stonehouse | Director, President & CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Dec 2023 | 595,000 | 595,000 | - | - | Emp. Stock Option (Right to Buy) | |
| Biocryst Pharma Inc | Stonehouse Jon P. | Director, President & CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Dec 2023 | 127,500 | 1,142,451 (0%) | 0% | 0 | Common Stock | |
| Biocryst Pharma Inc | Stonehouse P. Jon | Director, President & CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 6.43 per share. | 14 Dec 2023 | 13,592 | 1,128,859 (0%) | 0% | 6.4 | 87,397 | Common Stock |
| Biocryst Pharma Inc | Jon P. Stonehouse | Director, President & CEO | Gift of securities by or to the insider at price $ 0.00 per share. | 13 Jun 2023 | 25,000 | 1,014,794 (0%) | 0% | 0 | Common Stock | |
| Biocryst Pharma Inc | Jon P. Stonehouse | Director, President & CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 21 Mar 2023 | 31,055 | 305,995 | - | - | Emp. Stock Option (Right to Buy) | |
| Biocryst Pharma Inc | Jon P. Stonehouse | Director, President & CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 3.22 per share. | 21 Mar 2023 | 31,055 | 1,039,794 (0%) | 0% | 3.2 | 99,997 | Common Stock |
| Biocryst Pharma Inc | Jon P. Stonehouse | Director, President & CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Feb 2023 | 100,000 | 0 | - | - | Emp. Stock Option (Right to Buy) | |
| Biocryst Pharma Inc | Jon P. Stonehouse | Director, President & CEO | Sale of securities on an exchange or to another person at price $ 10.38 per share. | 01 Feb 2023 | 100,000 | 1,008,739 (0%) | 0% | 10.4 | 1,038,000 | Common Stock |
| Biocryst Pharma Inc | Jon P. Stonehouse | Director, President & CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 5.45 per share. | 01 Feb 2023 | 100,000 | 1,108,739 (0%) | 0% | 5.5 | 545,000 | Common Stock |
| Biocryst Pharma Inc | Jon P. Stonehouse | Director, President & CEO | Gift of securities by or to the insider at price $ 0.00 per share. | 01 Feb 2023 | 10,000 | 1,008,739 (0%) | 0% | 0 | Common Stock | |
| Biocryst Pharma Inc | Jon P. Stonehouse | Director, President & CEO | Gift of securities by or to the insider at price $ 0.00 per share. | 01 Feb 2023 | 5,000 | 10,000 (0%) | 0% | 0 | Common Stock | |
| Biocryst Pharma Inc | Jon P. Stonehouse | Director, President & CEO | Gift of securities by or to the insider at price $ 0.00 per share. | 01 Feb 2023 | 5,000 | 10,000 (0%) | 0% | 0 | Common Stock | |
| Biocryst Pharma Inc | Jon P. Stonehouse | Director, President & CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 19 Dec 2022 | 595,000 | 595,000 | - | - | Emp. Stock Option (Right to Buy) | |
| Biocryst Pharma Inc | Jon P. Stonehouse | Director, President & CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 19 Dec 2022 | 127,500 | 1,015,230 (0%) | 0% | 0 | Common Stock | |
| Biocryst Pharma Inc | Jon P. Stonehouse | Director, President & CEO | Sale of securities on an exchange or to another person at price $ 10.90 per share. | 15 Dec 2022 | 14,100 | 887,730 (0%) | 0% | 10.9 | 153,690 | Common Stock |
| Biocryst Pharma Inc | Jon P. Stonehouse | Director, President & CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 1.42 per share. | 01 Dec 2022 | 214,917 | 1,116,747 (0%) | 0% | 1.4 | 305,182 | Common Stock |
| Biocryst Pharma Inc | Jon P. Stonehouse | Director, President & CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Dec 2022 | 214,917 | 82,656 | - | - | Emp. Stock Option (Right to Buy) | |
| Biocryst Pharma Inc | Jon P. Stonehouse | Director, President & CEO | Sale of securities on an exchange or to another person at price $ 13.00 per share. | 01 Dec 2022 | 214,917 | 901,830 (0%) | 0% | 13 | 2,793,921 | Common Stock |
| Biocryst Pharma Inc | Jon P. Stonehouse | Director, President & CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Dec 2022 | 82,656 | 0 | - | - | Emp. Stock Option (Right to Buy) | |
| Biocryst Pharma Inc | Jon P. Stonehouse | Director, President & CEO | Sale of securities on an exchange or to another person at price $ 12.80 per share. | 01 Dec 2022 | 82,656 | 901,830 (0%) | 0% | 12.8 | 1,057,997 | Common Stock |
| Biocryst Pharma Inc | Jon P. Stonehouse | Director, President & CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 1.42 per share. | 01 Dec 2022 | 82,656 | 984,486 (0%) | 0% | 1.4 | 117,372 | Common Stock |
| Biocryst Pharma Inc | Jon P. Stonehouse | Director, President & CEO | Sale of securities on an exchange or to another person at price $ 15.04 per share. | 11 Jan 2022 | 184,000 | 901,602 (0%) | 0% | 15.0 | 2,767,360 | Common Stock |
| Biocryst Pharma Inc | Jon P. Stonehouse | Director, President & CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 11 Jan 2022 | 184,000 | 0 | - | - | Emp. Stock Option (Right to Buy) | |
| Biocryst Pharma Inc | Jon P. Stonehouse | Director, President & CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 4.73 per share. | 11 Jan 2022 | 184,000 | 1,085,602 (0%) | 0% | 4.7 | 870,320 | Common Stock |
| Biocryst Pharma Inc | Jon P. Stonehouse | Director, President & CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Dec 2021 | 574,500 | 574,500 | - | - | Emp. Stock Option (Right to Buy) | |
| Biocryst Pharma Inc | Jon P. Stonehouse | Director, President & CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Dec 2021 | 123,000 | 901,602 (0%) | 0% | 0 | Common Stock | |
| Biocryst Pharma Inc | Jon P. Stonehouse | Director, President & CEO | Gift of securities by or to the insider at price $ 0.00 per share. | 14 Dec 2021 | 5,000 | 783,602 (0%) | 0% | 0 | Common Stock | |
| Biocryst Pharma Inc | Jon P. Stonehouse | Director, President & CEO | Gift of securities by or to the insider at price $ 0.00 per share. | 14 Dec 2021 | 5,000 | 5,000 (0%) | 0% | 0 | Common Stock | |
| Biocryst Pharma Inc | Jon P. Stonehouse | Director, President & CEO | Gift of securities by or to the insider at price $ 0.00 per share. | 14 Dec 2021 | 5,000 | 5,000 (0%) | 0% | 0 | Common Stock | |
| Biocryst Pharma Inc | Jon P. Stonehouse | Director, President & CEO | Gift of securities by or to the insider at price $ 0.00 per share. | 14 Dec 2021 | 5,000 | 778,602 (0%) | 0% | 0 | Common Stock |